Zobrazeno 1 - 10
of 23
pro vyhledávání: '"J. J. Miranda. Geelhoed"'
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 11 (2017)
Idiopathic pulmonary fibrosis (IPF) is a devastating, progressive and ultimately fatal lung disease. The combination of poor prognosis, uncertainty of disease course and severe symptom burden heavily impacts patients’ and their families’ quality
Externí odkaz:
https://doaj.org/article/08a649b547a74a97b99a83c31db26851
Autor:
Annemie M W J Schols, Anke H Maitland-van der Zee, Joop P van den Bergh, Sebastiaan Holverda, Esther J Nossent, Els J M Weersink, Marianne A van de Pol, Firdaus A A Mohamed Hoesein, Lisanne T Schuurman, Ivo van der Lee, Jelle M Blankestijn, Mahmoud I Abdel-Aziz, Nadia Baalbaki, Somayeh Bazdar, Inés Beekers, Rosanne J H C G Beijers, Lizan D Bloemsma, Merel E B Cornelissen, Debbie Gach, Laura Houweling, John J L Jacobs, Reneé Jonker, Paulien M A Linders, Lieke C E Noij, Daphne W Schaminee, Brigitte Sondermeijer, J J Miranda Geelhoed, Yolanda de Wit-van Wijck
Publikováno v:
BMJ Open Respiratory Research, Vol 11, Iss 1 (2024)
Background Four months after SARS-CoV-2 infection, 22%–50% of COVID-19 patients still experience complaints. Long COVID is a heterogeneous disease and finding subtypes could aid in optimising and developing treatment for the individual patient.Meth
Externí odkaz:
https://doaj.org/article/08cab7016402442e9e9b869081c263bd
Autor:
Philippine Kiès, Liesbeth J J Beaart-van de Voorde, Maarten K Ninaber, Maarten E Tushuizen, Anja Corsel, Talitha Dhondai, J J Miranda Geelhoed-Veltman, Marlies E Heuvers
Publikováno v:
RMD Open, Vol 9, Iss 2 (2023)
Background Since 2009, Dutch patients with a confirmed diagnosis/suspicion of systemic sclerosis (SSc) can be referred to the Leiden Combined Care in Systemic Sclerosis (CCISS) cohort. This study evaluated whether early recognition of SSc has improve
Externí odkaz:
https://doaj.org/article/fd84ee86a96c49fb8571f0ad6a188a2a
Autor:
Ebru Dirikgil, Kim Brons, Michael Duindam, Geert H Groeneveld, J J Miranda Geelhoed, Christian Heringhaus, Paul J M van der Boog, Ton J Rabelink, Willem Jan W Bos, Niels H Chavannes, Douwe E Atsma, Y K Onno Teng
Publikováno v:
JMIR Formative Research, Vol 6, Iss 7, p e38263 (2022)
BackgroundDuring the COVID-19 pandemic, several home monitoring programs have described the success of reducing hospital admissions, but only a few studies have investigated the experiences of patients and health care professionals. ObjectiveThe obj
Externí odkaz:
https://doaj.org/article/0fb3d47a53e04817b398af4162fe4ae0
Autor:
Sophie I E Liem, Jacopo Ciaffi, Nina Marijn van Leeuwen, Maaike Boonstra, Saad Ahmed, Liesbeth J J Beaart-van de Voorde, Anja Corsel, Talitha Dhondai, Maarten K Ninaber, J J Miranda Geelhoed-Veltman, Marlies E Heuvers, Maarten E Tushuizen, Nina Ajmone Marsan, Philippine Kiès, Anne A Schouffoer, Tom W J Huizinga, Cornelia F Allaart, Jeska De Vries-Bouwstra
Publikováno v:
RMD Open. 9:e002971
BackgroundSince 2009, Dutch patients with a confirmed diagnosis/suspicion of systemic sclerosis (SSc) can be referred to the Leiden Combined Care in Systemic Sclerosis (CCISS) cohort. This study evaluated whether early recognition of SSc has improved
Autor:
Gizal Nakshbandi, Catharina C. Moor, Esther J. Nossent, J. J. Miranda Geelhoed, Sara J. Baart, Bart G. Boerrigter, Joachim G. J. V. Aerts, Suzan F. M. Nijman, Helger Y. Santema, Merel E. Hellemons, Marlies S. Wijsenbeek
Publikováno v:
Respirology, 27(7), 501-509. Wiley-Blackwell Publishing Ltd
Nakshbandi, G, Moor, C C, Nossent, E J, Geelhoed, J J M, Baart, S J, Boerrigter, B G, Aerts, J G J V, Nijman, S F M, Santema, H Y, Hellemons, M E & Wijsenbeek, M S 2022, ' Home monitoring of lung function, symptoms and quality of life after admission with COVID-19 infection : The HOMECOMIN' study ', Respirology, vol. 27, no. 7, pp. 501-509 . https://doi.org/10.1111/resp.14262
Respirology, 27(7), 501-509. Wiley-Blackwell
Respirology, 27(7), 501-509. WILEY
Nakshbandi, G, Moor, C C, Nossent, E J, Geelhoed, J J M, Baart, S J, Boerrigter, B G, Aerts, J G J V, Nijman, S F M, Santema, H Y, Hellemons, M E & Wijsenbeek, M S 2022, ' Home monitoring of lung function, symptoms and quality of life after admission with COVID-19 infection : The HOMECOMIN' study ', Respirology, vol. 27, no. 7, pp. 501-509 . https://doi.org/10.1111/resp.14262
Respirology, 27(7), 501-509. Wiley-Blackwell
Respirology, 27(7), 501-509. WILEY
Background and objective: To develop targeted and efficient follow-up programmes for patients hospitalized with coronavirus disease 2019 (COVID-19), structured and detailed insights in recovery trajectory are required. We aimed to gain detailed insig
Autor:
Bas Floris Maria Van Raaij, Maarten K. Ninaber, J. J. Miranda Geelhoed, J. Lauran Stöger, J.F. Annoeska Hameete
Publikováno v:
Respiratory infections and bronchiectasis.
Autor:
Job J.M.H. van Bragt, Michiel Alexander de Raaf, Harm Jan Bogaard, Pierre M Bet, Azar Kianzad, Merlijn Reijrink, Esther J. Nossent, Job R Schippers, Lucas R Celant, Lieuwe D. J. Bos, Jeroen N. Wessels, Mirte Muller, Chris Happé, Niels Pronk, Anton Vonk Noordegraaf, Leo M. A. Heunks, Liza Botros, E Marleen Kemper, Wim Boersma, Michel van den Heuvel, Hans P Grotjohan, Rianne J A Hoek, Carolina C Pamplona, Sara Azhang, Nicole P. Juffermans, Marry R Smit, Ivo van der Lee, Imke H Bartelink, Bas F M van Raaij, Janneke E Stalenhoef, Wouter Hoefsloot, Pieter R. Tuinman, Ariana Lammers, Katrien Eger, Boaz D Hazes, E Laurien van der Lee, Karin A T Boomars, Arthur L E M Vanhove, Frances S. de Man, Laura A Hagens, Anke-Hilse Maitland-van der Zee, Elisabeth C W Neefjes, Marcus J. Schultz, Pearl F M Mau Asam, Erik Duijvelaar, Patrick J Smeele, A. Josien Smits, Frank W J M Smeenk, Elise M A Slob, Laurien M A Oswald, Ary Serpa Neto, J. J. Miranda Geelhoed, Jessie Van Wezenbeek, Gert-Jan Braunstahl, Herman M A Hofstee, Romke Hoekstra, Peter I. Bonta, Jurjan Aman, Nienke Paternotte, Renate Kos, Ahmed A. Bayoumy, Peter W A Kunst, Maria J Overbeek, Adinda Mieras, Yurika L E van Glabbeek
Publikováno v:
lancet. Respiratory medicine, 9(9), 957-968. Elsevier Limited
The Lancet Respiratory Medicine, 9(9), 957-968. ELSEVIER SCI LTD
The Lancet Respiratory Medicine, 9(9), 957-968. Elsevier Ltd.
Lancet Respiratory Medicine, 9, 957-968
Aman, J, Duijvelaar, E, Botros, L, Kianzad, A, Schippers, J R, Smeele, P J, Azhang, S, Bartelink, I H, Bayoumy, A A, Bet, P M, Boersma, W, Bonta, P I, Boomars, K A T, Bos, L D J, van Bragt, J J M H, Braunstahl, G-J, Celant, L R, Eger, K A B, Geelhoed, J J M, van Glabbeek, Y L E, Grotjohan, H P, Hagens, L A, Happe, C M, Hazes, B D, Heunks, L M A, van den Heuvel, M, Hoefsloot, W, Hoek, R J A, Hoekstra, R, Hofstee, H M A, Juffermans, N P, Kemper, E M, Kos, R, Kunst, P W A, Lammers, A, van der Lee, I, van der Lee, E L, Maitland-van der Zee, A-H, Mau Asam, P F M, Mieras, A, Muller, M, Neefjes, L, Nossent, E J, Oswald, L M A, Overbeek, M J, Pamplona, C, Paternotte, N, Pronk, N, de Raaf, M A, van Raaij, B F M, Reijrink, M, Schultz, M J, Serpa Neto, A, Slob, E M, Smeenk, F W J M, Smit, M R, Smits, A J, Stalenhoef, J E, Tuinman, P R, Vanhove, A L E M, Wessels, J N, van Wezenbeek, J C C, Vonk Noordegraaf, A, de Man, F S & Bogaard, H J 2021, ' Imatinib in patients with severe COVID-19 : a randomised, double-blind, placebo-controlled, clinical trial ', Lancet respiratory medicine, vol. 9, no. 9, pp. 957-968 . https://doi.org/10.1016/S2213-2600(21)00237-X
The Lancet. Respiratory Medicine
Lancet respiratory medicine, 9(9), 957-968. Elsevier Limited
Lancet Respiratory Medicine, 9, 9, pp. 957-968
The Lancet Respiratory Medicine
The Lancet Respiratory Medicine, 9(9), 957-968. ELSEVIER SCI LTD
The Lancet Respiratory Medicine, 9(9), 957-968. Elsevier Ltd.
Lancet Respiratory Medicine, 9, 957-968
Aman, J, Duijvelaar, E, Botros, L, Kianzad, A, Schippers, J R, Smeele, P J, Azhang, S, Bartelink, I H, Bayoumy, A A, Bet, P M, Boersma, W, Bonta, P I, Boomars, K A T, Bos, L D J, van Bragt, J J M H, Braunstahl, G-J, Celant, L R, Eger, K A B, Geelhoed, J J M, van Glabbeek, Y L E, Grotjohan, H P, Hagens, L A, Happe, C M, Hazes, B D, Heunks, L M A, van den Heuvel, M, Hoefsloot, W, Hoek, R J A, Hoekstra, R, Hofstee, H M A, Juffermans, N P, Kemper, E M, Kos, R, Kunst, P W A, Lammers, A, van der Lee, I, van der Lee, E L, Maitland-van der Zee, A-H, Mau Asam, P F M, Mieras, A, Muller, M, Neefjes, L, Nossent, E J, Oswald, L M A, Overbeek, M J, Pamplona, C, Paternotte, N, Pronk, N, de Raaf, M A, van Raaij, B F M, Reijrink, M, Schultz, M J, Serpa Neto, A, Slob, E M, Smeenk, F W J M, Smit, M R, Smits, A J, Stalenhoef, J E, Tuinman, P R, Vanhove, A L E M, Wessels, J N, van Wezenbeek, J C C, Vonk Noordegraaf, A, de Man, F S & Bogaard, H J 2021, ' Imatinib in patients with severe COVID-19 : a randomised, double-blind, placebo-controlled, clinical trial ', Lancet respiratory medicine, vol. 9, no. 9, pp. 957-968 . https://doi.org/10.1016/S2213-2600(21)00237-X
The Lancet. Respiratory Medicine
Lancet respiratory medicine, 9(9), 957-968. Elsevier Limited
Lancet Respiratory Medicine, 9, 9, pp. 957-968
The Lancet Respiratory Medicine
Background The major complication of COVID-19 is hypoxaemic respiratory failure from capillary leak and alveolar oedema. Experimental and early clinical data suggest that the tyrosine-kinase inhibitor imatinib reverses pulmonary capillary leak. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95b9388602de3565960dbc68949c8a0a
https://pure.amc.nl/en/publications/imatinib-in-patients-with-severe-covid19(40a385b0-de53-45cd-aff2-cb6b5cdfc6d3).html
https://pure.amc.nl/en/publications/imatinib-in-patients-with-severe-covid19(40a385b0-de53-45cd-aff2-cb6b5cdfc6d3).html
Autor:
Samuel Knauss, Spencer Rezek, Stefano Barco, J. J. Miranda Geelhoed, Matthias Endres, Bob Siegerink, Jörg Janne Vehreschild, Gudula J. A. M. Boon, Frederikus A. Klok, Martijn A. Spruit
Publikováno v:
European Respiratory Journal, 56(1):2001494. European Respiratory Society
The European Respiratory Journal
article-version (AM) Accepted Manuscript
The European Respiratory Journal
article-version (AM) Accepted Manuscript
Since the outbreak of the Coronavirus disease 2019 (COVID-19) pandemic, most attention has focused on containing transmission of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and addressing the surge of critically ill patients in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::050caeb5549d9dad6cce2231cbfbbf9e
https://cris.maastrichtuniversity.nl/en/publications/a68bc3d9-04fd-4ddc-af03-cf8ca4bc6bd0
https://cris.maastrichtuniversity.nl/en/publications/a68bc3d9-04fd-4ddc-af03-cf8ca4bc6bd0
Publikováno v:
Therapeutic Advances in Respiratory Disease, 11(3), 157-169. SAGE Publications Ltd
Therapeutic Advances in Respiratory Disease, Vol 11 (2017)
Therapeutic Advances in Respiratory Disease, Vol 11 (2017)
Idiopathic pulmonary fibrosis (IPF) is a devastating, progressive and ultimately fatal lung disease. The combination of poor prognosis, uncertainty of disease course and severe symptom burden heavily impacts patients’ and their families’ quality